Clinical trial • Phase I • Oncology|Infectious Disease
Clinical trial in Graft-versus-host disease
Phase I trial for Graft-versus-host disease. 8 participants.
Overview
- Trial Therapeutic Area
- Oncology|Infectious Disease
- Trial Disease
- Graft-versus-host disease
- Trial Stage
- Phase I
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 02-08-2024
- First CTIS Authorization Date
- 18-11-2024
Trial design
Phase I trial across 1 site in Spain.
- Target Sample Size
- 8
Eligibility
Recruits 8 Vulnerable populations not selected; no information on consent/assent available..
- Vulnerable Population
- Vulnerable populations not selected; no information on consent/assent available.
Recruitment
- Planned Sample Size
- 8
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 8
Spain
- Earliest CTIS Part Ii Submission Date
- 24-08-2024
- Latest Decision Or Authorization Date
- 18-11-2024
- Processing Time Days
- 86
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Hematology
- Contact Person Name
- Guillermo Orti
- Contact Person Email
- gorti@vhio.net
Sponsor
Primary sponsor
- Full Name
- Red De Apoyo A La Investigacion Clinica En Hematologia Y Hemoterapia S.L.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Spain
Co-sponsors
- Vall D Hebron Institute Of Oncology
Related trials
Other published trials that may interest you.
- Clinical trial in Graft-versus-host disease
- Amoxicillin, Clavulanic acid for Malignant brain tumor|Leptomeningeal dissemination
- N/A for Cervical dysplasia|Human papillomavirus (HPV) infection|Cervical intraepithelial neoplasia (CIN2+)
- Human papillomavirus L1 proteins (types 6, 11, 16, 18, 31, 33, 45, 52, 58) for Recipients of allogeneic stem cell transplantation